CDK4 and cholangiocarcinoma: Combination treatment with oxaliplatin and the CDK4/6 inhibitor palbociclib synergistically inhibited CCA cell proliferation and prevented the emergence of CDK4/6i and oxaliplatin-resistant CCA.